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Abstract
Pyruvate carboxylase (PC) catalyzes the conversion of pyruvate to oxaloacetate (OAA), an
important metabolic reaction in a wide range of organisms. Small molecules directed against
PC would enable detailed studies on the metabolic role of this enzyme and would have the
potential to be developed into pharmacological agents. Currently, specific and potent small
molecule regulators of PC are unavailable. To assist in efforts to find, develop, and

characterize small molecule effectors of PC, a novel fixed-time assay has been developed
based on the reaction of OAA with the diazonium salt, Fast Violet B (FVB), which produces a
colored adduct with an absorbance maximum at 530 nm. This fixed time assay is reproducible,
sensitive and responsive to known effectors of Rhizobium etli PC, Staphylococcus aureus PC,
and Listeria monocytogenes PC, and is highly amenable to high-throughput screening. The
assay was validated using a plate uniformity assessment test and a pilot screen of a library of
1280 compounds. The results indicate that the assay is suitable for screening small molecule
libraries to find novel small molecule effectors of PC.
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Introduction
Pyruvate carboxylase (PC) is a biotin-dependent metabolic enzyme that catalyzes the
conversion of pyruvate to oxaloacetate (OAA) through a MgATP-dependent carboxyl group
transfer from HCO3− to pyruvate. The reaction occurs in two distinct active sites located in the
biotin carboxylase (BC) and the carboxyltransferase (CT) domains of the enzyme [1]. A
tethered biotin cofactor is initially carboxylated by HCO3− in the BC domain, with the
concomitant cleavage of MgATP. The carboxybiotin cofactor is subsequently transferred to the
CT domain, which facilitates the carboxyl group transfer from carboxybiotin to pyruvate,
forming OAA [1]. This anaplerotic reaction serves to replenish tricarboxylic acid cycle (TCA)
intermediates that are lost to alternative biosynthetic reactions [2]. Recent studies have linked
aberrant PC activity to several diseases and infections, such as type 2 diabetes, listeriosis, and
certain types of cancers [[3], [4], [5], [6], [7], [8], [9], [10]]. Many of these studies have revealed a
correlation between reduced PC expression/activity and decreased insulin release, while
enhanced PC expression and activity has been associated with tumor cell proliferation and
breast cancer metastases [3,4,7,11]. Additionally, PC is necessary for the pathogenicity of Listeria
monocytogenes, a facultative intracellular bacterium [8,12,13].
While there is a growing realization that PC activity is implicated in a wide range of diseases
and infections, at present, there are no specific and potent small molecule effectors available
to study altered PC activity in vitro or in vivo. A number of small molecules are known to alter
PC activity [14,15], but none of these demonstrate high binding affinities and many of them are
promiscuous. Oxalate for example, is an inhibitor of PC with a Ki value of 12 μM (chicken liver
PC [14]), but is also a known metal chelator [16] that inhibits lactate dehydrogenase (LDH) [17]
and transcarboxylase [18]. Specific and potent small molecule effectors have great potential to
be used as biochemical tools to aid in delineating the structure, mechanism, and regulation of
PC, as well as informing on its role in infection and disease. The development of a highthroughput assay is an important prerequisite in discovering new and potent effectors of PC
activity.
Several well-established coupled-enzyme assays are available to study PC activity [19,20], but
none of these are well suited to high throughput screening (HTS) of small molecule effectors.
The PC-catalyzed carboxylation of pyruvate is typically measured by coupling the formation of

the product, OAA, to the malate dehydrogenase (MDH) catalyzed reduction of OAA to malate
and oxidation of NADH to NAD+ [20]. In addition, there are a variety of other coupled-enzyme
assays that can measure the specific half-reactions catalyzed in either the BC or CT domains.
For example, an LDH-coupled assay can be used to determine the rate of OAA
decarboxylation in the CT domain by the NADH-dependent reduction of pyruvate to lactate.
Similarly, a glucose-6-phospate dehydrogenase/phosphoglucomutase/phosphorylase coupled
assay system can be used to determine the rate of MgATP cleavage in the BC domain [19].
These coupled-enzyme assays are generally inappropriate for screening large libraries of
small molecules. For instance, the inclusion of secondary coupling enzymes raises the
potential for small molecules to target the coupling enzyme instead of, or in addition to, the
target enzyme. While counter-screens of small molecules against the coupling enzyme are
routinely implemented in HTS programs, these represent an additional step that must be
performed to eliminate false positives [21,22]. Furthermore, the vast majority of coupled-enzyme
assays make use of redox enzymes that act on NAD/NADH, requiring absorbance changes to
be monitored at 340 nm. This wavelength is suboptimal for the small assay volumes typical of
HTS assays, where short path lengths and low extinction coefficients limit the signal window in
a multi-well plate format [[23], [24], [25]]. Additionally, absorbance at 340 nm is subject to
interference from small molecules, dust particles and standard assay components [23,25],
resulting in an increased signal to noise ratio and an increased number of false positives.
To overcome the limitations associated with using coupled-enzyme assays, a novel 96-multiwell plate and fixed-time assay has been developed. The assay is based on the reaction of
OAA, the product of the PC-catalyzed reaction, with Fast Violet B (FVB), a diazonium salt
which produces a colored adduct with an absorbance maximum at 530 nm (Fig. 1). Diazonium
salts have previously been used to detect OAA formation in other enzymatic systems such as
phosphoenolpyruvate carboxylase and aspartate transaminase [[26], [27], [28], [29], [30]], but FVB has
never been applied to determine PC activity. The assay readout is stable for an extended time
period and accurately reports on enzyme activity from a single data point. The FVB fixed-time
assay is reproducible, sensitive and responsive to known effectors of PC. The assay was used
to screen a series of small molecule libraries that establishes it as an excellent primary assay
for a concerted HTS program directed against PC.

Fig. 1. Proposed mechanism for the reaction of oxaloacetate with Fast Violet B.

Materials and methods
Pyruvate carboxylase protein expression and purification
Rhizobium etli PC (RePC) was co-expressed from a modified pET-17b-(His)9 vector [31] with a
pCY216 vector [32] encoding E. coli biotin protein ligase (BirA) in E. coli BL21Star(DE3) cells.
Staphylococcus aureus PC (SaPC) [33] and Listeria monocytogenes PC (LmPC) were coexpressed from a pET-28a vector with a pCY216 vector in E. coli BL21Star(DE3) cells. RePC,
LmPC and SaPC were purified using Ni2+-affinity and anion exchange chromatography as
previously described [34]. In all cases, harvested cells were re-suspended in a lysis buffer
containing 20 mM Tris (pH 7.8), 5 mM imidazole, 200 mM NaCl, 0.5 mM EGTA, 6 mM 2mercaptoethanol, 300 μg/mL lysozyme, 1 mM phenylmethane-sulfonyl fluoride (PMSF), 1 μM
pepstatin A, and 5 μM proteinase inhibior E−64. Cells were disrupted by sonication and the cell
lysate was cleared by centrifugation at 4 °C prior to loading onto a 10 mL Ni2+-NTA Profinity
resin column (Bio-Rad Laboratories). The column was washed with 150 mL of lysis buffer
followed by 150 mL of wash buffer (20 mM Tris; pH 7.8, 20 mM imidazole, 200 mM NaCl,
0.5 mM EGTA, 6 mM 2-mercaptoethanol). The RePC enzyme was eluted from the column in
elution buffer (20 mM Tris; pH 7.8, 250 mM imidazole, 200 mM NaCl, 0.5 mM EGTA, 6 mM 2mercaptoethanol) with an 88 mL gradient of 20 mM imidazole wash buffer to 250 mM imidazole
elution buffer. For SaPC and LmPC, the enzymes were eluted in a single step elution with 25–
30 mL elution buffer.
All purified protein samples were pooled and dialyzed overnight in 1 L of Q-Sepharose buffer
containing 20 mM triethanolamine (pH 8.0), 50 mM NaCl, 1 mM EGTA, and 2 mM DTT at 4 °C
in preparation for anion exchange chromatography. Protein was loaded on a 10 mL column of
Q-Sepharose Fast Flow resin (GE Healthcare) and the column was washed with 60 mL of QSepharose buffer. The RePC protein was eluted from the resin in Q-Sepharose buffer using a
linear gradient from 50 mM to 1 M NaCl over 88 mL. For SaPC and LmPC, the enzymes were
eluted in a single step elution with 25–30 mL of Q-sepharose buffer containing 1 M NaCl.
Fractions were pooled and dialyzed against a storage buffer consisting of 10 mM Tris (pH 7.8),
150 mM KCl, 3 mM MgCl2, 5% (v/v) glycerol and 2 mM DTT. An Amicon stirred cell with a
30,000-molecular weight cutoff filter was used to concentrate protein preparations to a range of
3–12 mg/mL. Concentrated protein was flash-frozen in liquid nitrogen prior to storage at
−80 °C.

Preparation of assay reagents and solutions
All assay reagents and solutions were prepared separately and maintained at 22 °C for the full
duration of the experiments. All substrates, effectors and enzyme were freshly dissolved and
diluted in assay buffer containing 50 mM Bis-Tris (pH 7.7), 150 mM KCl, 3.0 mM MgCl2, 0.5%
triton X-100, and 1% DMSO. The final concentration of enzyme in the 100 μL enzymatic
reaction was 10 μg/mL, except for LmPC where the final concentration of enzyme in the 100 μL
enzymatic reaction was 50 μg/mL. Where noted, oxalate and acetyl coenzyme A (Crystal
Chem Inc., Elk Grove, IL) were included in the 100 μL enzymatic reaction at a final
concentration of 5 mM and 0.25 mM, respectively. The substrate solution containing NaHCO3,
pyruvate and ATP was added to the 100 μL enzymatic reaction at a final concentration of

25 mM, 2 mM, and 1 mM, respectively. EDTA was prepared in assay buffer and served to
inactivate the enzyme-catalyzed reaction at a final concentration of 12.7 mM. Fast Violet B Salt
(FVB; Santa Cruz Biotechnology) was prepared at a stock concentration of 46 mM in DMSO.
After vortexing the FVB stock solution to dissolve the dye, it was centrifuged at 9300 × g for
1 min and the clarified supernatant was separated from the salt pellet. The resulting FVB stock
solution was protected from light exposure until it was introduced into the assay.

Assay procedures
For all experiments other than the evaluation of the Library of Pharmacologically Active
Compounds (LOPAC, Sigma), 30 μL enzyme stock solution was added to each well in 96-well,
flat bottom, polystyrene microplates (Santa Cruz Biotechnology) followed by the addition of
10 μL of the effectors (oxalate for inhibition, acetyl CoA for activation, assay buffer for the uninhibited or un-activated reaction, and EDTA for measurement of the background signal). To
initiate the enzyme-catalyzed reaction, 60 μL of a substrate stock solution containing pyruvate,
HCO3− and ATP in assay buffer was added to each well. After 1 h, the enzyme reaction was
inactivated by the addition of 10 μL of EDTA, followed by the addition of 10 μL of FVB to a final
volume of 120 μL. The plates were sealed with microseal ‘B’ adhesive seals (Bio-Rad) and
incubated for 2 h at 22 °C, prior to measuring absorbance values at 530 nm. All plates and
reagents were maintained at 22 °C for the duration of the experiments. Reagents were
dispensed using an automated liquid handling system (MultiFlo FX, Biotek) except for the
effectors which were manually added using a hand-held, multi-channel micropipette. For the
LOPAC screens, the procedure was slightly modified to incorporate a pintool (V&P Scientific)
in combination with an Evo system (Tecan Life Sciences) to transfer the controls (0.4 μL) and
compounds (0.2 μL) after the addition of enzyme. After the addition of the controls, 70 μL of the
substrate stock solution was added to the wells to initiate the enzyme reaction.

Data analysis
The assay signal quality was statistically evaluated using the Z-factor value as described by
Equation (1) [35], where σs and σc represent the standard deviations for the sample and control,
respectively, and μs and μc represent the means for the sample and control, respectively.
𝑍𝑍 = 1 −

(3𝜎𝜎𝑠𝑠 +3𝜎𝜎𝑐𝑐 )
|𝜇𝜇𝑠𝑠 −𝜇𝜇𝑐𝑐 |

(1)

To determine the agreement of the assay in measuring PC activity, the kcat and KM for pyruvate
were determined by the following method: (1) An OAA standard curve was established to
relate absorbance values at 530 nm to the OAA concentration. The standard curve was linear
between 0 and 400 μM [OAA] (described in the results). (2) To determine the kcat and KM
values using the FVB assay, the enzyme-catalyzed reaction at varying concentrations of
pyruvate was inactivated at different time intervals. The absorbance values were then
converted to [OAA] using the standard curve. Initial velocities ([OAA]/minute) were determined
for each substrate concentration and plotted against pyruvate concentration. Equations (2), (3)
were used to determine kcat and KM values, where [E]T represents the total enzyme

concentration, vi represents initial velocity, Vmax represents the maximum velocity and [S]
represents the substrate concentration:
𝑣𝑣i =

Vmax [S]
𝐾𝐾M +[S]

𝑘𝑘cat =

Vmax
[E]T

(2)
(3)

The validation experiments were designed and evaluated according to the recommendations
of the “Assay Guidance Manual” from the National Center for Advancing Translational
Sciences (NCATS), which includes all necessary pre-configured spreadsheets for analysis of
the inter-plate and inter-day experiments [36].
For the LOPAC screen, percent activation and percent inhibition were calculated according to
the equations (4), (5), where μC, μE and μR represent the means for the control (addition of
acetyl CoA or oxalate), effector (screened small molecule), and reaction (the unaffected
reaction), respectively:
μ –μ

Percentactivation = 100 − ((μ C−μE ) × 100) (4)
C

R

μ –μ

C

Percentinhibition = 100 − ((μ E−μC ) × 100) (5)
R

To determine the potency of specific effectors, the FVB assay was performed at varying
effector concentrations. The dose-dependent response curves were evaluated using IC50 and
EC50 equations, according to equation [6]:
bottom+top−bottom

Y = 1+10(logIC50 −x)*hillslope) (6)

Curve fitting was performed using the software programs KaleidaGraph and Graphpad Prism.

Results
To accelerate the discovery of novel small molecule effectors of PC, it was necessary to
establish an assay that can accurately measure PC activity in a high-throughput manner.
Several diazonium salts have previously been utilized to detect OAA formation [26,27,29,30] but, to
the best of our knowledge, they have never been applied to assay PC activity. Consequently,
we sought to develop and validate a novel, fixed-time assay to measure PC activity via the
formation of a colored adduct between the reaction product, OAA, and the diazonium salt,
FVB.
FVB formed a colored adduct with OAA with an absorbance maximum at 530 nm, consistent
with previously reported studies (Fig. 2A) [26,27]. None of the other assay components (HCO3−,
pyruvate, ATP) contributed substantially to the absorbance at 530 nm in the presence of FVB,
resulting in a large signal to noise ratio for OAA under all assay conditions. The absorbance at

530 nm was linear over a wide range of OAA concentrations between 1 and 400 μM, but
deviated from linearity at OAA concentrations greater than ∼400 μM (Fig. 2B). This deviation
from linearity has previously been reported [26]. Because of this deviation, the accuracy of the
assay is expected to decrease at concentrations of OAA in excess of 400 μM. As such, the
assay was designed to maintain an upper limit of OD530 ∼1 to maximize the signal window
while ensuring accuracy. In this range, the assay is both reliable and sensitive in measuring
OAA formation as a function of PC activity.

Fig. 2. Absorbance spectrum and OAA standard curve in the presence of 4 mM FVB. A) The background
absorbance (yellow) in the assay was measured by the addition of the substrates (2.0 mM pyruvate, 1.0 mM ATP
and 25 mM HCO3−) and assay buffer. The absorbance spectra recorded in assay buffer in the presence of
substrates at varying concentrations of OAA are shown for 0.3 mM (pink), 0.6 mM (red) and 1.2 mM (purple) OAA.
B) The absorbance (530 nm) of the FVB-OAA adduct responds linearly to OAA concentrations between 1 and
400 μM (solid line, R2 = 0.99), while the dependence of absorbance on concentration begins to deviate from
linearity at concentrations greater than 400 μM. This deviation can be approximated by a second standard curve
between 400 and 800 μM (dashed line, R2 = 0.96). Error bars represent the standard deviation from eight
independent measurements. (For interpretation of the references to color in this figure legend, the reader is
referred to the Web version of this article.)

An assay procedure was developed according to the schematic described in Fig. 3. Assay
conditions were optimized for a 120 μL total reaction volume in a 96-well format. The assay
comprises three overall steps: 1) a PC catalyzed reaction, 2) PC inactivation with EDTA, and
3) incubation with FVB. PC was first added to the wells, followed by the addition of the small
molecule effector. The addition of the small molecules in this order facilitated the preincubation of the enzyme with effector molecules to account for potential slow-binding
activators or inhibitors [21]. The enzymatic reaction was initiated by the addition of a large
volume of substrates, to facilitate rapid and complete mixing in each well. EDTA was used to
inactivate the reaction by chelating and sequestering the essential Mg2+ ions from the BC
domain active site, immediately rendering the enzyme inactive [37] (Supplementary Figure S1).
Previous studies have also demonstrated that EDTA assists in preventing diazonium salt
precipitation [26]. Following enzyme inactivation, FVB was added and absorbance was
measured at 530 nm following a 2 h incubation.

Fig. 3. 96-well fixed-time assay procedure. The PC-catalyzed reaction is initiated by the addition of substrates
(2 mM pyruvate, 1 mM ATP, and 25 mM NaHCO3). After 1 h, the PC-catalyzed reaction is inactivated by the
addition of 12.7 mM EDTA. FVB is subsequently added to a final concentration of 4 mM for 2 h prior to reading the
absorbance of the FVB-OAA colored adduct at 530 nm. This procedure can be performed manually or with an
automated liquid handling system.

To test the ability of the assay to detect activators and inhibitors of PC, the assay procedure
was validated by measuring the absorbance of the colored FVB-OAA adduct in the presence
of acetyl CoA (activator) and oxalate (inhibitor). The activator and inhibitor were used to test
the reliability and signal window of the assay as a prerequisite for its application in small
molecule dose-dependent measurements. The background reaction was measured in the
presence of inactivating EDTA and resulted in similar absorbance values (∼0.2 Abs) as the
inhibited reaction in the presence of 5 mM oxalate. The activated reaction in the presence of
0.25 mM acetyl CoA resulted in an increase in absorbance (∼1.0–1.2 Abs) when compared to
the unaltered reaction without any small molecule effectors added (∼0.5–0.6 Abs). The EC50
value for acetyl CoA (45 μM) and the IC50 value for oxalate (97 μM) were determined for RePC
(Fig. 4). These values are consistent with published KA and KD values of 10 μM and 130 μM,
respectively, thus further confirming the reliability of this method [38,39]. These results strongly
support that the FVB assay can be simultaneously utilized to screen for both activators and
inhibitors of PC in a HTS program.

Fig. 4. FVB assay optimization and dose dependent response with known effectors of RePC. A) The primary
assay method was evaluated in the presence of established effectors of PC activity. The “background” signal was

determined from the reaction of PC in the presence of 12.7 mM EDTA. The “reaction” signal was determined from
the reaction of PC in the absence of any effectors. The “activation” signal was determined from the reaction of PC
in the presence of the activator, acetyl CoA (0.25 mM). The “inhibition” signal was determined from the reaction of
PC in the presence of the inhibitor, oxalate (5 mM). The differences between the group means were statistically
significant, as determined by one-way ANOVA (F (3, 28) = 5956, p < 0.0001). B) Titration of acetyl CoA gives an
EC50 value for acetyl CoA of 45 μM. C) Titration of oxalate gives an IC50 value for oxalate of 97 μM. In all plots,
error bars represent the standard deviation from eight independent measurements.

To further assess the reliability of this assay, steady-state kinetic constants were determined
for Rhizobium etli PC (RePC). RePC has been extensively structurally and kinetically
characterized in the presence of both oxalate and acetyl-CoA, serving as an ideal model
system for validation. The KM value for pyruvate (1.5 ± 0.3 mM) and the kcat value (120 ± 20
min−1) were determined for RePC (Supplementary Figure S2) and are consistent with
previously reported values [40,41].
Assays that are transitioned to HTS need to not only be reliable, accurate and sensitive but
also robust, reproducible and statistically validated [35]. To assess the quality of the assay to be
transitioned to a HTS platform, PC was statistically evaluated in the presence of both acetyl
CoA and oxalate. Z-factors can be utilized to compare, evaluate and validate the suitability of
an assay for HTS. A Z-factor score of 0.5–1.0 indicates that the assay has a high dynamic
range and low variation in the signal measurements and is an excellent assay. Z′-factors are
used to determine the overall quality of the assay without interference from small molecule
effectors. Alternatively, Z-factors take into account the signal separation and error of the assay
when used with small molecule activators or inhibitors. In order to determine the robustness
and quality of the assay, Z-factors and Z′-factors were calculated for RePC, Listeria
monocytogenes PC (LmPC) and Staphylococcus aureus PC (SaPC) (Table 1). PC enzymes
from multiple source organisms were selected to determine the suitability of various bacterial
PC enzymes for HTS. The excellent Z-factors for RePC, LmPC and SaPC demonstrate that
this assay is amenable to high-throughput screening for both activators and inhibitors of PC
enzymes from a range of organisms. The results suggest, however, that assay conditions must
be individually optimized for PC enzymes from different species, as demonstrated by the
increased enzyme concentration (50 μg/mL) required to obtain high Z-factors in the assay
catalyzed by LmPC.
Table 1. Z- Factors Determined for the assay of bacterial PC enzymes.
PC Origin

Enzyme
Z′-Factor
[ ] μg/mL

Z-Factor Activation

Z-Factor Inhibition

Assay Score

Rhizobium etli

10

0.86

0.85

0.87

Excellent

Listeria monocytogenes

50

0.70

0.77

0.70

Excellent

Staphylococcus aureus

10

0.87

0.87

0.87

Excellent

In consideration of using this assay in a HTS context, a series of additional optimization and
validation tests were performed using automatic liquid dispensing protocols. Most small
molecules from screening libraries are dissolved in DMSO and are added at fixed
concentrations in the screening assays. Thus, it was necessary to evaluate the tolerance of PC
for DMSO [36]. PC activity was not affected by the presence of 1% DMSO (Supplementary

Figure S3). Additionally, all reagents were stable at 22 °C for up to 8 h, and the final measured
absorbance values were stable between 2 and 5 h of incubation with FVB (Fig. 5). A three-day
plate uniformity assessment using the interleaved-signal format [36] was performed in the
presence of the inhibitor, oxalate. This demonstrated that the signal windows, Z-factors and
spatial uniformity meet all criteria for consistent plate readouts across multiple plates and days
(Fig. 6A). A two-day validation test was performed for activation in the presence of acetyl CoA,
demonstrating consistent plate readouts across multiple plates and days (Fig. 6B;
Supplementary Table S1).

Fig. 5. Reagent and signal stability for the FVB-based assay. In all plots, the background signal (black) represents
the inactivated PC reaction in the presence of 12.7 mM EDTA. The reaction signal (grey) represents the PC
reaction in the absence of effectors. The activation signal (green) represents the PC reaction in the presence of
the activator, acetyl-CoA (0.25 mM). The inactivation signal (blue) represents the PC reaction in the presence of
the inhibitor, oxalate (5 mM). A) All reagents used in the FVB-based assay are stable under all conditions for up to
8 h at 22 °C. The first assay was run at time zero with freshly prepared reagents. These same reagents were used
for all subsequent reactions, yielding consistent measurements for up to 480 min beyond the time of the first
assay. B) Incubation times between 120 and 300 min yield consistent absorbance measurements, indicating that
the FVB-OAA color adduct is stable for an extended time period, permitting the measurement of plates at any
time between 2 and 5 h post-incubation with FVB. In both plots, error bars represent the standard deviation from
eight independent measurements. (For interpretation of the references to color in this figure legend, the reader is
referred to the Web version of this article.)

Fig. 6. Plate uniformity validation tests for RePC with oxalate and acetyl-CoA. Both plate uniformity tests reveal
consistent signals across all plates and across multiple days. Well number 0–96, 97–192 and 193–288 refer to
Day 1, Day 2 and Day 3, respectively. No edge or drift effects were observed and all statistical measures are
acceptable. A) 3-day inhibition plate uniformity assessment with 5 mM oxalate for the minimal signal (blue
diamonds), 90 μM oxalate for the IC50 signal (pink squares) and the uninhibited PC reaction for the maximal signal
(green triangles). B) 2-day activation plate uniformity assessment with 250 μM acetyl-CoA as the maximal signal
(green triangles), 50 μM acetyl-CoA for the EC50 signal (pink squares) and the uninhibited PC reaction as the
minimal signal (blue diamonds). (For interpretation of the references to color in this figure legend, the reader is
referred to the Web version of this article.)

The FVB assay was used to screen RePC against a LOPAC library (Library of
Pharmacologically Active Compounds, Sigma) to validate the responsiveness of the assay to a
library of well-characterized bioactive compounds. RePC was screened against the LOPAC
library on three separate occasions and reproducibly identified two inhibitors in all three
iterations of the screen (Fig. 7). Consistent activation and inhibition signals were obtained for
individual plate controls across all 16 plates and all plates had excellent Z-factors (Fig. 7A and
B). The screen identified two compounds that resulted in 70–91% inhibition (Fig. 7D). The two
hit compounds, cisplatin and pyriplatin, were confirmed by dose-dependent response assays,
yielding IC50 values of 22 μM and 30 μM, respectively (Fig. 8). While the steep dose-response
curve for these compounds suggests that they are likely acting as non-specific alkylating

agents [42,43] or promiscuous aggregators [44], the results from the pilot screen nevertheless
indicate that the assay can reproducibly and reliably identify an appropriate number of potential
inhibitor hit compounds. The LOPAC pilot screen did not identify any potential activators for
RePC, indicating that a larger, more diverse library is required to identify activators (Fig. 7C).
All optimization and validation results indicate that the assay is reproducible, reliable and
sufficiently sensitive to detect a range of small molecule effectors of PC within screening
libraries.

Fig. 7. LOPAC (Library of Pharmacologically Active Compounds) screen results for inhibitors and activators of
Rhizobum etli PC. A) Absorbance signals for individual plate controls. The maximal signal is determined in the
presence of 250 μM acetyl-CoA (pink squares), the normal PC reaction is determined in the absence of effectors
(purple squares) and the inhibited reaction is determined in the presence of 5 mM oxalate (blue squares). Error
bars represent the standard deviation from eight independent measurements. B) Z-factors fall in a range
considered to be excellent (0.6–0.8) and are consistent across all 16 plates. C) Percent of activation from Screen
1 of the LOPAC screen D) Combined inhibition data from three individual LOPAC screens (Screen 1, blue;
Screen 2, pink; and Screen 3, purple). The dashed line represents a threshold of 3× the standard deviation for the
combined data, equivalent to 45% inhibition. Two compounds consistently exceeded this threshold across all

three screens. (For interpretation of the references to color in this figure legend, the reader is referred to the Web
version of this article.)

Fig. 8. Dose dependent response for the two inhibitors, cisplatin and pyriplatin, identified in the LOPAC screen. A)
Dose-dependent response for the inhibition of R. etli PC in the presence of cisplatin results in an IC50 value of
22 μM. B) Dose-dependent response for the inhibition of R. etli PC in the presence of pyriplatin results in an IC50
value of 30 μM. The chemical structures of the hit compounds and the percent of inhibition measured in each of
the three independent screens are indicated. In both plots, error bars represent the standard deviation from eight
independent measurements.

Discussion
A novel, fixed time assay for PC has been developed that is reliable, sensitive and robust. The
assay monitors the production of OAA through the formation of a colored adduct between OAA
and the commercially available diazonium salt of FVB. This offers a simple assay to detect PC
activity through monitoring an increase in absorbance at 530 nm. The assay can be utilized as
an alternative method to coupled-enzyme assays for the detection of PC activity. Additionally,
the assay can readily be transitioned to a multi-well plate format where the reagent stability,
accuracy and reproducibility is ideal for use in high-throughput screening of small molecule
libraries for both activators and inhibitors of PC activity.
While diazonium salts have previously been used to detect the production of OAA, they have
not specifically been applied to assay PC activity. Diazonium salts such as Fast Red KL, Fast
Ponceau L and Fast Violet B have been used to detect OAA production from aspartate
transaminase [26,28,45,46]. Fast Violet B, in particular, has also been utilized to assess
phosphoenolpyruvate carboxylase activity and has previously been optimized in a microtiter
plate assay [27,29]. The choice of Fast Violet B over other diazonium salts in this assay is based

on several factors. Fast Violet B is stable over a pH range of 7.0–7.5 and tolerates the addition
of both EDTA and detergent [27,28,45,47]. Conversely, Fast Red KL and Fast Ponceau L were
most stable over a pH range of 4.2–4.6 [26,28,45,46]. Additionally, Fast Violet B has a broad
absorption peak between 490 and 540 nm compared to the narrower absorption peaks of Fast
Red KL and Fast Ponceau L (455–467 nm respectively), enabling greater flexibility in the
assay parameters [26,28]. The red-shifted absorbance wavelength of FVB also reduces the
likelihood of interference with small molecule effectors. Lastly, FVB has previously been used
in a microtiter plate-based assay for phosponenolpyruvate carboxylase, indicating that it is
amenable to the smaller reaction volumes typical of a high throughput screening assay.
The FVB-based assay is capable of accurately measuring steady state kinetics in PC,
consistent with a study by Amador and Salvatore (1971) that compared the activity of
aspartate aminotransferase measured by FVB and Fast Ponceau L to the rates determined by
a MDH coupled-enzyme assay. Thus, the FVB fixed-time assay can be employed as an
alternative to the MDH coupled-enzyme assay for standard kinetic measurements of PC
activity in instances where assay conditions interfere with the coupling enzyme. For example,
many α-keto acids serve as inhibitors of PC [38] but MDH has been shown to reduce aromatic
α-keto acids [48], precluding careful inhibition studies using the standard MDH coupled enzyme
assay. The FVB-based enzyme assay is free of secondary coupling enzymes that might
otherwise be subject to cross-reactivity and, as such, represents an important and
complementary tool for detailed kinetic studies of PC. It must be noted that the reaction times
employed for measuring initial velocity kinetics (0–60 s; Supplementary Figure S2) are
substantially different from the reaction time that is employed in the high throughput screening
applications (1 h; Fig. 4, Fig. 5, Fig. 6). In high throughput screening, a 1 h enzyme-catalyzed
reaction produces an ideal signal window for screening PC effectors, despite deviating from
initial velocity conditions. Thus, the enzyme reaction times must be selected to coincide with
the assay objectives: 1 h for high throughput screening vs. 10–60 s for measuring initial
velocity kinetics.
While it has many advantages, the FVB assay also has certain limitations that must be
carefully considered. FVB, like all diazonium salts, has the potential for cross-reactivity with
nucleophilic compounds. For example, it has previously been demonstrated that FVB forms a
colored adduct with α-ketoglutarate [26] and occasionally produced false positives due to
ketosis in serums [46]. Additionally, FVB reacts with high concentrations (>250 μM) of acetyl
CoA and CoA, resulting in a decrease in the FVB-OAA adduct (Supplementary Figure S4).
Thus, small molecule activators may be difficult to identify if their interference with FVB-OAA
colored adduct formation offsets their enhancement of PC activity. This may be one reason
why PC activators were not observed in the LOPAC screen. It is also likely, however, that it is
simply more difficult to find activators of PC, as allosteric ligands are generally more difficult to
detect by HTS [49].
Lastly, consideration should be given to determining the appropriate concentration of
substrates to be used in the FVB assay, particularly where it is being applied as a HTS primary
screen. Here, the assay has been performed at 2 mM pyruvate, which is less than the
saturating concentrations of 5–20 mM pyruvate, depending on the source of the PC enzyme.
This sub-saturating concentration of pyruvate maximizes the signal to noise ratio of the assay

for RePC but, notably, has not been optimized for LmPC or SaPC. The substrate
concentrations in a HTS assay will influence the detection of weak inhibitors [22,50]. It was
determined by Yang et al. that performing inhibitor screens at substrate concentrations near to
the KM value is ideal to detect competitive, non-competitive and uncompetitive inhibitors [50].
Thus, prior to embarking on a detailed HTS program, it will be important to consider the
substrate concentrations in relation to the KM values of the substrates, particularly if certain
types of inhibitors (i.e. competitive vs. non-competitive) are being sought against a PC target
from a desired organism.
In conclusion, a novel, fixed-time assay to detect PC activity has been established. This assay
can be used to screen for small molecule effectors of PC or as an alternative method to
measure steady state enzyme kinetics. The development and validation of this assay will
enable future HTS for the discovery of small molecule effectors of PC. The resulting small
molecules that will be discovered and developed using this assay will have great potential as
biochemical tools to further investigate the regulation and structure of PC, as well as the
metabolic role that it plays in infection and disease.

Appendix A. Supplementary data
The following is the supplementary data related to this article:
Download Acrobat PDF file (785KB)Help with pdf files
Multimedia component 1.
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